J Heinlin1, G Isbary, W Stolz, F Zeman, M Landthaler, G Morfill, T Shimizu, J L Zimmermann, S Karrer. 1. Department of Dermatology, University Hospital Regensburg, Regensburg, Germany Department of Dermatology, Hospital Munich-Schwabing, Munich, Germany Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany Max-Planck Institute for Extraterrestrial Physics, Garching, Germany.
Abstract
BACKGROUND: To look into new potential indications for physical plasma and because some reports suggest plasma having antipruritic effects, we investigated the treatment of pruritus that often represents a therapeutic challenge. OBJECTIVES: To assess the efficacy and safety of cold atmospheric argon plasma as add-on-therapy in pruritic diseases. METHODS: We treated 46 patients with various pruritic diseases with cold plasma for 2 min daily in addition to standard treatment. All patients served as their own control, when their pruritic disease was treated with argon gas (placebo). The outcome measure was a long-term and short-term reduction in itching measured by means of a visual analogue score (VAS). RESULTS: The VAS scores at baseline were comparable (plasma 4.57, SD 2.38, argon 4.34, SD 2.35). We did not find any significant differences in VAS reduction between plasma and argon: long-term VAS difference of 1.97 (SD 1.33) for plasma and 1.74 (SD 2.37) for argon [P = 0.224, 95% CI: (-0.15; 0.60)], short-term VAS difference of 1.92 (SD 1.33) for plasma and 1.97 (SD 1.29) for argon [P = 0.544, 95% CI: (-0.21; 0.11)]. In both groups, patients experienced a significant reduction of pruritus at the end of therapy compared to baseline [plasma 1.97 (P < 0.0001), placebo 1.74 [P < 0.0001)]. No relevant side effects occurred, and treatment was well tolerated. CONCLUSIONS: Treatment with cold plasma did not result in higher pruritus reduction than treatment with placebo. A significant reduction of pruritus compared to no effect was found at the end of therapy in both groups. Both treatment options had similar safety profiles.
RCT Entities:
BACKGROUND: To look into new potential indications for physical plasma and because some reports suggest plasma having antipruritic effects, we investigated the treatment of pruritus that often represents a therapeutic challenge. OBJECTIVES: To assess the efficacy and safety of cold atmospheric argon plasma as add-on-therapy in pruritic diseases. METHODS: We treated 46 patients with various pruritic diseases with cold plasma for 2 min daily in addition to standard treatment. All patients served as their own control, when their pruritic disease was treated with argon gas (placebo). The outcome measure was a long-term and short-term reduction in itching measured by means of a visual analogue score (VAS). RESULTS: The VAS scores at baseline were comparable (plasma 4.57, SD 2.38, argon 4.34, SD 2.35). We did not find any significant differences in VAS reduction between plasma and argon: long-term VAS difference of 1.97 (SD 1.33) for plasma and 1.74 (SD 2.37) for argon [P = 0.224, 95% CI: (-0.15; 0.60)], short-term VAS difference of 1.92 (SD 1.33) for plasma and 1.97 (SD 1.29) for argon [P = 0.544, 95% CI: (-0.21; 0.11)]. In both groups, patients experienced a significant reduction of pruritus at the end of therapy compared to baseline [plasma 1.97 (P < 0.0001), placebo 1.74 [P < 0.0001)]. No relevant side effects occurred, and treatment was well tolerated. CONCLUSIONS: Treatment with cold plasma did not result in higher pruritus reduction than treatment with placebo. A significant reduction of pruritus compared to no effect was found at the end of therapy in both groups. Both treatment options had similar safety profiles.
Authors: Jan-Wilm Lackmann; Simon Schneider; Eugen Edengeiser; Fabian Jarzina; Steffen Brinckmann; Elena Steinborn; Martina Havenith; Jan Benedikt; Julia E Bandow Journal: J R Soc Interface Date: 2013-09-25 Impact factor: 4.118
Authors: Stephanie Arndt; Michael Landthaler; Julia L Zimmermann; Petra Unger; Eva Wacker; Tetsuji Shimizu; Yang-Fang Li; Gregor E Morfill; Anja-Katrin Bosserhoff; Sigrid Karrer Journal: PLoS One Date: 2015-03-13 Impact factor: 3.240
Authors: Jesús Gay-Mimbrera; Maria Carmen García; Beatriz Isla-Tejera; Antonio Rodero-Serrano; Antonio Vélez García-Nieto; Juan Ruano Journal: Adv Ther Date: 2016-05-03 Impact factor: 3.845
Authors: Julian Balzer; Kiara Heuer; Erhan Demir; Martin A Hoffmanns; Sabrina Baldus; Paul C Fuchs; Peter Awakowicz; Christoph V Suschek; Christian Opländer Journal: PLoS One Date: 2015-12-14 Impact factor: 3.240